Psychiatry Research: Neuroimaging
Volume 148, Issue 2 , Pages 175-183 , 1 December 2006

Dopamine D2 receptor occupancy by risperidone: Implications for the timing and magnitude of clinical response

  • Ana M. Catafau

      Affiliations

    • Departments of Nuclear Medicine and Psychiatry, St Pau Hospital, U.A.B. (Autónoma University from Barcelona), Barcelona, Spain
    • GSK Centre for Imaging in Psychiatry, Clinical Pharmacology Discovery Medicine, Psychiatry, Centre of Excellence for Drug Discovery, Barcelona, Spain
    • ,
  • Iluminada Corripio

      Affiliations

    • Departments of Nuclear Medicine and Psychiatry, St Pau Hospital, U.A.B. (Autónoma University from Barcelona), Barcelona, Spain
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, Sta. Creu and St. Pau Hospital, C/ Sant Antoni Maria Claret 167, 08025 Barcelona, Spain.
    • ,
  • Victor Pérez

      Affiliations

    • Departments of Nuclear Medicine and Psychiatry, St Pau Hospital, U.A.B. (Autónoma University from Barcelona), Barcelona, Spain
    • ,
  • Juan Carlos Martin

      Affiliations

    • Department of Nuclear Medicine, Parc Taulí Hospital, Sabadell, Barcelona, Spain
    • ,
  • Alain Schotte

      Affiliations

    • Janssen Research Foundation, Beerse, Belgium
    • ,
  • Ignasi Carrió

      Affiliations

    • Departments of Nuclear Medicine and Psychiatry, St Pau Hospital, U.A.B. (Autónoma University from Barcelona), Barcelona, Spain
    • ,
  • Enric Alvarez

      Affiliations

    • Departments of Nuclear Medicine and Psychiatry, St Pau Hospital, U.A.B. (Autónoma University from Barcelona), Barcelona, Spain

Received 6 March 2005 ,Accepted 2 February 2006.

References 

  1. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:8104–8109
  2. Bernardo M, Parellada E, Lomeña F, Catafau AM, Font M, Gomez JC, et al. Double-blind olanzapine versus haloperidol D2 receptor blockade in schizophrenic patients: a baseline–endpoint 123I-IBZM SPECT study. Psychiatry Research: Neuroimaging. 2001;107:87–97
  3. Brücke T, Roth J, Podreka I, Strobl R, Wenger S, Asenbaum S. Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet. 1992;339:497
  4. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. Journal of Toxicology. Clinical Toxicology. 2001;39:1–14
  5. Catafau AM. Brain SPECT in clinical practice. Part I: perfusion. Journal of Nuclear Medicine. 2001;42:259–271
  6. De Haan L, Lavalaye J, Linszen D, Dingemans PM, Booji J. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. American Journal of Psychiatry. 2000;157:1019–1020
  7. Dresel S, Tatsch K, Dahne I, Mager T, Scherer J, Hahn K. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in risperidone-treated schizophrenic patients. Journal of Nuclear Medicine. 1998;39:1138–1142
  8. Farde L, Wiesel FA, Nordström AL, Sedvall G. D1- and D2-dopamine receptor occupancy during treatment during conventional and atypical neuroleptics. Psychopharmacology. 1989;99:28–31
  9. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Archives of General Psychiatry. 1992;49:538–543
  10. Farde L, Mack RJ, Nyberg S, Halldin C. D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. International Clinical Psychopharmacology. 1997;12:3–7
  11. Fitzgerald PB, Kapur S, Remington G, Roy P, Zipursky RB. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology. 2000;149:1–5
  12. Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology. 1998;135:119–126
  13. Grace AA, Bunney BS, Moore H, Todd CL. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends in Neuroscience. 1997;20:31–37
  14. Guardia J, Catafau AM, Batlle F, Martin JC, Segura L, Gonzalvo B, et al. Striatal dopaminergic D2 receptor density measured by [123I] iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients. American Journal of Psychiatry. 2000;157:127–129
  15. Innis RB. Neuronal transmission. In:  Wagner HN,  Szabo Z,  Buchanan JW editor. Principles of Nuclear Medicine. Philadelphia: WB Saunders Company; 1995;p. 497–504
  16. Joyce JN. D2 but not D3 receptors are elevated after 9 or 11 months of chronic haloperidol treatment: influence of withdrawal period. Synapse. 2001;40:137–144
  17. Kapur S, Seeman P. Does fast disassociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. American Journal of Psychiatry. 2001;158:360–369
  18. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transient high dopamine D2 receptor occupancy. Archives of General Psychiatry. 2000;57:553–559
  19. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276
  20. Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, et al. 123I IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. American Journal of Psychiatry. 1996;153:183–190
  21. Knable MB, Heinz A, Raedler T, Weinberger DR. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Research: Neuroimaging. 1997;75:91–101
  22. Küfferle B, Brücke T, Topitz-Schratzberger A, Tauscher J, Gossler R, Vesely C, et al. Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. Psychiatry Research: Neuroimaging. 1996;68:23–30
  23. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Quarterly Journal of Nuclear Medicine. 1998;42:211–221
  24. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophrenia Bulletin. 1991;17:263–287
  25. Nyberg S, Farde L, Bartfai A, Halldin C. Central D2 receptor occupancy and effects of zuclopenthixol in humans. International Clinical Psychopharmacology. 1995;10:221–227
  26. Nyberg S, Farde L, Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. 1997;16:1–7
  27. Olesen OV, Linnet K. Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients co-medicated with other psychotropic drugs. Journal of Chromatography B. Biomedical Sciences and Applications. 1997;698:209–216
  28. Overall JE, Gorham DE. The Brief Psychiatric Rating Scale. Psychological Reports. 1962;10:799–812
  29. Parellada E, Catafau A, Bernardo M, Lomena F, Catarineu S, Gonzalez-Monclus E. The resting and activation issue of hypofrontality: a single photon emission computed tomography study in neuroleptic-naïve and neuroleptic-free schizophrenic female patients. Biological Psychiatry. 1998;44:787–790
  30. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet. 1992;340:199–202
  31. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I-IBZM SPECT. Psychological Medicine. 1993;23:791–797
  32. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others?. Psychopharmacology. 2000;148:3–15
  33. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 1996;124:57–73
  34. Schröder J, Silvestri S, Bubeck B, Karr M, Demisch S, Scherrer S, et al. D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naïve state and after neuroleptic treatment. Biological Psychiatry. 1998;43:660–665
  35. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. 1970;212:11–19
  36. Tauscher J, Küfferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, et al. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology. 1999;141:175–181

PII: S0925-4927(06)00024-2

doi: 10.1016/j.pscychresns.2006.02.001

Psychiatry Research: Neuroimaging
Volume 148, Issue 2 , Pages 175-183 , 1 December 2006

Article Tools

* Image Usage & Resolution